



UPREGULATION OF MATRIX
METALLOPROTEINASES – 2 AND -9
AND
TYPE IV COLLAGEN DEGRADATION
IN
SKELETAL MUSCLE REPERFUSION INJURY

Denise Margaret Roach, MBBS, DDU, FRACS.

**Thesis submitted to The University of Adelaide
For the Degree of Doctor of Medicine,
January 2002.**

**The work described was performed within the Department of Surgery,
The University of Adelaide, The Queen Elizabeth Hospital, Adelaide, Australia)**

Table of Contents

CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW OF REPERFUSION INJURY AND MATRIX METALLOPROTEINASES	1
1.1 Introduction	2
1.2 Ischaemia.....	4
1.3 Reperfusion injury.....	5
1.3.1 Effects of Skeletal Muscle Ischaemia/Reperfusion Injury on Remote Organs	6
1.3.1.1 Cardiac effects of Skeletal Muscle Ischaemia/Reperfusion Injury	6
1.3.1.2 Lung effects of Skeletal Muscle Ischaemia/Reperfusion Injury	7
1.3.1.3 Gastrointestinal effects of Skeletal Muscle Ischaemia/Reperfusion Injury	8
1.3.1.4 Renal effects of Skeletal Muscle Ischaemia/Reperfusion Injury	8
1.3.2 Pathophysiology of Reperfusion Injury in Skeletal Muscle.....	9
1.3.2.1 Increased Microvascular Permeability	9
1.3.2.2 Reactive Oxygen Species	10
1.3.2.3 Lipid Peroxidation.....	12
1.3.2.4 Nitric Oxide (Endothelium Derived Relaxing Factor)	12
1.3.2.5 No-reflow Phenomenon.....	13
1.3.2.6 Neutrophils	14
1.3.2.7 Eicosanoids.....	17
1.3.2.8 Intracellular Calcium Ion.....	19
1.3.2.9 Complement	19
1.3.2.10 Cytokines.....	20
1.3.2.11 Endothelin.....	22
1.3.3 Therapeutic regimes to ameliorate Ischaemia/Reperfusion Injury.....	23
1.3.3.1 Supportive Clinical Measures to decrease the effects of Ischaemia/Reperfusion	24
1.3.3.2 Controlled Reperfusion	25
1.3.3.3 Free Radical Scavengers and Inhibitors	25
1.3.3.4 Neutrophil Inhibition	26
1.3.3.5 Complement Activation.....	26
1.3.3.6 Antioxidants	26
1.3.3.7 Ischaemic Preconditioning	26
1.3.3.8 Other Therapeutic Regimes to ameliorate Ischaemia/Reperfusion Injury:	27

1.4 Matrix Metalloproteinases.....	29
1.4.1 Introduction	29
1.4.2 Classification	30
1.4.2.1 MMP Structure	32
1.4.2.2 Collagenases	32
1.4.2.3 Gelatinases.....	33
1.4.2.4 Stromelysins	34
1.4.2.5 Membrane-type MMPs.....	34
1.4.2.6 Others:	35
1.4.3 Endogenous MMP Inhibition	37
1.4.3.1 α_2 -Macroglobulin	37
1.4.3.2 Tissue Inhibitors of Metalloproteinases (TIMPS).....	37
1.4.4 Control mechanisms and Activation of MMP-2 and MMP-9.....	38
1.4.4.1 MMP-2	38
1.4.4.2 MMP-9	40
1.4.5 Known roles of Matrix Metalloproteinases in Vascular Tissues.....	44
1.4.5.1 Atherosclerosis	44
1.4.5.2 Restenosis at Angioplasty Sites.....	45
1.4.5.3 Aortic Aneurysm Formation.....	46
1.4.6. Therapeutic Inhibition of MMPs	47
1.4.6.1 Blocking the Production of MMPs.....	47
1.4.6.2 Inhibition of Active MMPs by Chelators	48
1.5 Matrix metalloproteinases and reperfusion injury	50
1.5.1 Brain Ischaemia/Reperfusion injury and MMPs	50
1.5.2 Lung Ischaemia/Reperfusion injury and MMPs.....	50
1.5.3 Myocardial ischaemia/Reperfusion injury and MMPs.....	51
1.5.4 Renal Ischaemia/Reperfusion injury and MMPs.....	51
1.6 Aims of the Current Studies	52

CHAPTER 2: ESTABLISHMENT AND VALIDATION OF AN ANIMAL MODEL OF SKELETAL MUSCLE ISCHAEMIA/REPERFUSION INJURY

2.1 Introduction	54
2.2 Methods	55
2.2.1 Animal Model Protocol	55
2.2.2 Quantitation of Lung Oedema	56

Statistical analysis of Wet/Dry Weight Ratios in Lung Tissue	57
2.2.3 Histopathological Assessment of Tissue Damage.....	57
2.3 Results.....	67
2.3.1 Animal Model and Utilization.....	67
2.3.2 Quantitation of Lung Oedema	67
Statistical analysis of Wet/Dry Weight Ratios in Lung Tissue	67
2.3.3 Histopathological Assessment of Tissue Damage.....	69
2.3.3.1 Qualitative Analysis	69
2.3.3.2 Quantitative Analysis	70
2.4 Discussion	81
2.4.1 Animal Model and Utilization.....	81
2.4.2 Quantitation of Lung Oedema	85
2.4.3 Histopathological Assessment of Tissue Damage.....	87
CHAPTER 3: ELEVATED ACTIVITY OF MATRIX METALLOPROTEINASES-2 AND -9 DURING SKELETAL MUSCLE ISCHAEMIA/REPERFUSION INJURY.....	91
3.1 Introduction	92
3.2 Methods	93
3.2.1 Zymography	93
3.2.1.1. Tissue Preparation	93
3.2.1.2 Bio-Rad Protein Assay	93
3.2.1.3 Zymography Gel Preparation	94
3.2.1.4 Zinc Chelation	95
3.2.2 Western Blots	95
3.3 Results.....	97
3.3.1 Zymography	97
3.3.1.1 Confirmational Studies.....	97
3.3.1.2 Comparative studies of Zymographic detection of Gelatinolytic activity at varying Reperfusion times and between Sham-operated, Unilaterally and Bilaterally ischaemic animals.....	97
3.3.2 Western Blot Analysis.....	99
3.4 Discussion	111

CHAPTER 4: DEGRADATION OF TYPE IV COLLAGEN DURING SKELETAL MUSCLE ISCHAEMIA/REPERFUSION INJURY.....	114
4.1 Introduction	115
4.1.1 Type IV Collagen	116
4.1.2 Basement membrane structure	117
4.1.3 Immunohistochemical Techniques	118
4.2 General Immunohistochemical methods.....	121
4.2.1 Pilot studies, Negative Controls and Histogram levels	126
4.2.2 Determination of the Number of Images required for Reproducibility.....	126
4.2.3 Thickness of Tissue Sections.....	127
4.2.4 Quenching of Fluorescence by the Microscope Lamp	127
4.2.5 Antibody Saturation.....	128
4.2.6 Quantitative Immunohistochemistry	128
4.2.7 Descriptive Statistics	129
4.3 Results.....	130
4.3.1 Pilot studies, Negative Controls and Histogram levels	130
4.3.2 Determination of the Number of Images required for Reproducibility of Brightness Measurement	138
4.3.3 Thickness of Tissue Sections.....	143
4.3.4 Quenching of Tissue Fluorescence by the Microscope Lamp.....	146
4.3.5 Antibody Saturation.....	146
4.3.6 Quantitative Immunohistochemistry	153
4.3.6.1 Left leg Skeletal Muscle.....	153
4.3.6.2 Right leg	155
4.3.6.3 Lung.....	157
4.3.6.4 Kidney	160
4.3.6.5 Effect of Increasing Duration of Reperfusion on Levels of Type IV Collagen .	170
4.3.6.6 Differences between Type IV Collagen Levels in Sham-operated, Unilaterally Ischaemic and Bilaterally Ischaemic Rats.....	171
4.4 Discussion	181
4.4.1 MMP-2, MMP-9 and Type IV Collagen	181
4.4.2. Immunohistochemical Technique	183
4.4.3. Degradation of Type IV Collagen during Ischaemia/Reperfusion Injury.....	185

CHAPTER 5: THE LOCAL AND REMOTE EFFECTS OF DOXYCYCLINE IN SKELETAL MUSCLE REPERFUSION INJURY.....	189
5.1 Introduction	190
5.1.1 Doxycycline Rationale	190
5.2 Methods	193
5.2.1 Quantitation of Lung Oedema	193
5.2.2 Histopathological Assessment of Tissue Damage.....	193
5.2.3 Zymographic Analysis of Matrix Metalloproteinase Activity	194
5.2.4 Effect of Doxycycline on Degradation of Type IV Collagen during Skeletal Muscle Ischaemia/Reperfusion Injury	194
5.3 Results.....	195
5.3.1.Histopathological Assessment of Tissue Damage.....	195
5.3.1.1 Qualitative Analysis	195
5.3.1.2 Quantitative Analysis	196
5.3.2 Zymographic Analysis of Matrix Metalloproteinase Expression.....	203
5.3.3 Effect of Doxycycline on Degradation of Type IV Collagen during Skeletal Muscle Ischaemia/Reperfusion Injury	203
5.4 Discussion	212
5.4.1 Histopathological Assessment of Tissue damage.....	212
5.4.2 Zymographic Analysis of Matrix Metalloproteinase Expression.....	212
5.4.3 Effect of Doxycycline on Degradation of Type IV Collagen during Skeletal Muscle Ischaemia/Reperfusion Injury	212
 CHAPTER 6: SUMMARY, FUTURE DIRECTIONS AND CONCLUSIONS	 215
6.1 Summary of Chapters	216
Chapter 2	217
Chapter 3	218
Chapter 4	218
Chapter 5	221
6.2 Future Directions.....	222
6.3 Conclusions	223
 CHAPTER 7 APPENDICES	 225
7.1 Abbreviations.....	226
7.2 Chemicals and Reagents	228

7.3 Equipment	230
7.4 Buffers and Solutions	231
7.4.1 Homogenising Buffer for Zymography.....	231
7.4.2 Dialysis Buffer for Zymography	231
7.4.3 Resolving gel for Zymography.....	231
7.4.4 Stacking gel For Zymography and Western blots	232
7.4.5 Zymogram Loading Buffer.....	232
7.4.6. Western Loading buffer.....	232
7.4.7 Zymogram and Western Blot Tank/Running Buffer.....	232
7.4.8 Zymogram Development Buffer	233
7.4.9 Coomassie Blue Stain for Zymography	233
7.4.10 Destain for Zymography.....	233
7.4.11 Resolving Gel for Western Blot Analysis	233
7.4.12 Western Transfer Buffer.....	234
7.4.13 Non-fat Powdered Milk Solution	234
7.4.14 Tris Buffered saline for Western Blots.....	234
7.4.15 Western Antibody Buffer	234
7.4.16 Phosphate Buffered Saline for Immunohistochemistry.....	234
7.5 Immunohistochemical Methods	235
7.5.1 Slide preparation for Immunohistochemistry	235
7.5.2 Video Camera Correction Programme	235
7.6 Immunohistochemical Brightness results – Complete Data Sets	236
7.6.1 Pilot studies, Negative Controls and Histograms	236
7.6.2 Number of images required for Reproducibility Studies	240
7.6.3 Thickness of tissue sections studies	242
7.6.4 Quenching of Fluorescence Studies	243
7.6.5 Antibody Saturation.....	244
7.6.6 Quantitative Immunohistochemistry, Complete Data Sets	247
7.6.7 Quantitative Immunohistochemistry, Summary Data Sets	271
7.7.8 Quantitative Immunohistochemistry with Doxycycline, Complete Data Sets.....	277
7.7.9 Quantitative Immunohistochemistry with Doxycycline, Summary Data Sets.....	288
 CHAPTER 8: REFERENCES	 291

Abstract

Aims and objectives: To determine the role of the matrix metalloproteinases, MMP-2 and MMP-9, in reperfusion injury following skeletal muscle ischaemia and to determine whether inhibition of MMPs by doxycycline protects against tissue damage.

Methods: Sprague Dawley rats were anaesthetised and a tourniquet applied above the greater trochanter to occlude blood flow. Sham-operated rats underwent four hours of ischaemia and were sacrificed after 0, 4, 24 or 72 hours. Four hours of unilateral or bilateral lower limb ischaemia was followed by reperfusion for 0, 4, 24 or 72 hours. Two groups of rats received 50 mg/kg or 200 mg/kg twice daily doxycycline for 7 days prior to bilateral ischaemia and 24 hours of reperfusion. Rats were euthanased and skeletal muscle from both limbs, pulmonary and renal tissues were harvested for wet/dry weight lung ratios, histopathological analysis, zymography, western blot analysis and immunohistochemical staining for type IV collagen.

Results: Histopathological analysis confirmed the validity of the animal model with significant tissue damage seen in ischaemic skeletal muscle and kidney. Upregulation of MMP-2 and MMP-9 was seen on zymography in the ischaemic leg and lung but not in the kidney. Western blot analysis with MMP-9 antibody confirmed the zymographic findings. Quantitative immunohistochemical analysis of levels of type IV collagen, showed degradation in reperfused muscle, lung and kidney. There was less upregulation of MMP-2 and MMP-9 in the skeletal muscle seen on zymography following pre-treatment with doxycycline. Doxycycline treated rats showed significant preservation of type IV collagen in skeletal muscle and partial protection from type IV collagen degradation in lung and kidney. The lung wet/dry weight ratios showed no statistical difference between sham-operated and ischaemic animals.

Conclusions: MMP-2 and MMP-9 are strongly upregulated in skeletal muscle ischaemia/reperfusion injury and are also upregulated in remote organs, leading to degradation of membranes. Inhibition of MMP activity may therefore be potentially therapeutically useful in reducing the severity of reperfusion injury.